Wafik S. El-Deiry: Dr. Pingping Hou speaks on KRAS-targeted therapy and cellular plasticity
Wafik S. El-Deiry shared the following on LinkedIn:
“Dr. Pingping Hou at Rutgers University speaks about pancreatitis-induced (cerulin) resistance to KRAS-targeted therapy and cellular plasticity. Dr. Hou spoke about macrophage-TGF-beta EMT in regulation of KRAS bypass that requires SMAD4.”
Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023